Related Experiment Videos
Recombinant AAV-mediated gene delivery to the central nervous system
L Tenenbaum1, A Chtarto, E Lehtonen
1Laboratory of Experimental Neurosurgery, Université Libre de Bruxelles, Hôpital Erasme, 808, Route de Lennik, B-1070 Brussels, Belgium. litenenb@ulb.ac.be
The Journal of Gene Medicine
|February 24, 2004
Summary
Recombinant adeno-associated virus (rAAV) vectors show promise for brain gene therapy, with cellular promoters enabling sustained expression. Different rAAV serotypes target specific brain cells, and while antibodies form, gene expression remains stable, allowing for potential therapeutic applications.
Area of Science:
- Neuroscience
- Gene Therapy
- Molecular Biology
Background:
- Recombinant adeno-associated virus (rAAV) vectors are effective for gene transfer in the brain with no observed toxicity.
- Cytomegalovirus immediate early (CMV) promoter-driven expression declines over time, unlike sustained expression from cellular or hybrid promoters.
Purpose of the Study:
- To evaluate the efficacy and characteristics of rAAV-mediated gene transfer in the central nervous system (CNS).
- To explore the potential of rAAV vectors for therapeutic gene delivery in various neurological disorders.
Main Methods:
- Utilized different rAAV serotypes (e.g., rAAV2, rAAV5, rAAV1, rAAV4) for gene transfer in various brain regions.
- Employed various promoters (CMV, neuron-specific enolase, chicken beta-actin/CMV) to assess transgene expression stability.
- Investigated cellular tropism and immune responses following rAAV administration.
Main Results:
- Cellular promoters and hybrid promoters (chicken beta-actin/CMV) ensure sustained transgene expression compared to CMV promoter.
- rAAV serotypes exhibit distinct tropism: rAAV2 targets neurons, rAAV5/1 target neurons and glial cells, and rAAV4 targets ependymal cells.
- No inflammatory response was observed with rAAV2; antibodies to capsid/transgene product formed but did not reduce expression, allowing successful re-administration.
Conclusions:
- rAAV vectors, particularly with cellular promoters, offer a viable strategy for sustained gene expression in the CNS.
- The serotype-dependent tropism allows for targeted gene delivery to specific cell types within the brain.
- rAAV-based gene therapy holds significant potential for treating neurological diseases, though further vector development is needed for clinical translation.